FDA to hold adcomm for Grail cancer test that failed in large, randomized trialnews2026-08-07T16:08:57+00:00August 7th, 2026|Endpoints News|
Merck KGaA makes largest deal in a decade in $11.3B buy for Bio-Technenews2026-06-25T15:23:10+00:00June 25th, 2026|Endpoints News|
#ASCO26: Grail’s cancer blood test isn’t ready for widespread use, experts saynews2026-05-30T23:59:07+00:00May 30th, 2026|Endpoints News|
Grail names new CEO as Bob Ragusa retiresnews2026-03-13T03:23:06+00:00March 13th, 2026|Endpoints News|
Roche, Element and Ultima push toward the $100 genomenews2026-03-05T20:17:26+00:00March 5th, 2026|Endpoints News|
Why did my doctor push Grail’s dubious cancer test?news2026-02-26T17:09:28+00:00February 26th, 2026|Endpoints News|
Swiss Rockets buys MGI subsidiary Complete Genomics after Biosecure Actnews2026-02-23T19:56:05+00:00February 23rd, 2026|Endpoints News|
Grail’s cancer test faces new uncertainty after UK studynews2026-02-20T20:09:44+00:00February 20th, 2026|Endpoints News|
Grail’s cancer test misses primary study goal in UK studynews2026-02-20T03:19:15+00:00February 20th, 2026|Endpoints News|
Illumina bets on healthcare after Trump administration’s NIH funding disruptionsnews2026-02-06T09:19:24+00:00February 6th, 2026|Endpoints News|
